Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neurología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
ClinicalTrials.gov
Maximum Expiratory Pressure in Induced Cough as a Predictor of Extubation Failure in Intensive Care Unit Patients on Mechanical Ventilation Ready to Extubate. A Single-arm Open Clinical Trial.
INTERVENTIONAL
Inicio: 1 de oct de 2018
ID: NCT04356625
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de sept de 2010
ID: NCT01194414
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Double-Blind, Placebo-Controlled, Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinson's Disease.
INTERVENTIONAL
Inicio: 1 de abr de 2003
ID: NCT00058838
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (GD3) Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ERT)
INTERVENTIONAL
Inicio: 18 de abr de 2022
ID: NCT05222906
Terminado
Fase 3
ClinicalTrials.gov
A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301
INTERVENTIONAL
Inicio: 15 de feb de 2013
ID: NCT01797965
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
INTERVENTIONAL
Inicio: 10 de sept de 2013
ID: NCT01877915
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures
INTERVENTIONAL
Inicio: 17 de feb de 2011
ID: NCT01262677
Completado
Fase 3
ClinicalTrials.gov
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes
INTERVENTIONAL
Inicio: 25 de abr de 2013
ID: NCT01730534
Terminado
Fase 3
ClinicalTrials.gov
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
INTERVENTIONAL
Inicio: 9 de ago de 2012
ID: NCT01633112
Completado
Fase 3
ClinicalTrials.gov
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
INTERVENTIONAL
Inicio: 11 de jun de 2019
ID: NCT03872401
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
INTERVENTIONAL
Inicio: 12 de may de 2025
ID: NCT06563895
Desconocido
ClinicalTrials.gov
Multiple Sclerosis Registry in Argentina (RelevarEM)
OBSERVATIONAL
Inicio: 25 de mar de 2018
ID: NCT03375177
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 24 de jul de 2020
ID: NCT04222972
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy
INTERVENTIONAL
Inicio: 1 de oct de 2007
ID: NCT00548405
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
INTERVENTIONAL
Inicio: 14 de mar de 2024
ID: NCT06132893
Reclutando
ClinicalTrials.gov
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
OBSERVATIONAL
Inicio: 4 de mar de 2014
ID: NCT02071134
Completado
Fase 2
ClinicalTrials.gov
A Phase 2 Study of Doripenem In The Treatment of Nosocomial and Ventilator-Associated Pneumonia In Hospitals
INTERVENTIONAL
Inicio: 1 de ago de 2007
ID: NCT00502801
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
INTERVENTIONAL
Inicio: 25 de jun de 2021
ID: NCT04629248
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
INTERVENTIONAL
Inicio: 27 de oct de 2017
ID: NCT03299049
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)
INTERVENTIONAL
Inicio: 11 de mar de 2019
ID: NCT03823300
Anterior
1
...
19
20
21
...
434
Siguiente
Filtros